Golden State Equity Partners Has $231,000 Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 35.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 266,484 shares of the biopharmaceutical company’s stock after buying an additional 69,368 shares during the quarter. Golden State Equity Partners’ holdings in Sangamo Therapeutics were worth $231,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System raised its stake in Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Sangamo Therapeutics in the 2nd quarter worth about $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at about $89,000. Finally, Vontobel Holding Ltd. boosted its position in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 241,440 shares in the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. StockNews.com began coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $2.67.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO opened at $1.70 on Friday. The firm has a market cap of $353.98 million, a P/E ratio of -1.23 and a beta of 1.23. Sangamo Therapeutics, Inc. has a 52-week low of $0.29 and a 52-week high of $2.30. The business’s 50 day simple moving average is $0.97 and its two-hundred day simple moving average is $0.71.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. On average, equities analysts forecast that Sangamo Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.